An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care

An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

LBCTR

Registry ID

LBCTR2020043495

Enrollment

1000

Registered

2020-11-04

Start date

2020-04-27

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Covid-19

Interventions

Local standard of care alone, OR local standard of care plus one of: Remdesivir Chloroquine or hydroxychloroquine (suspended) Lopinavir with Ritonavir (suspended) Lopinavir with Ritonavir plus inte

as per the hospital standards

Daily infusion for 10 days

standard care

Remdesivir

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Eligibility: consenting adults (age =18) hospitalised with definite COVID-19, not already receiving any of the study drugs, without known allergy or contra-indications to any of them (in the view of the physician responsible for their care), and without anticipated transfer within 72 hours to a non-study hospital. Patients invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected.

Exclusion criteria

Exclusion criteria: Exclusion from study entry: Patients will not be randomised if, in the view of the randomising doctor, ANY of the AVAILABLE study drugs are contra-indicated (eg, because of patient characteristics, chronic liver or heart disease, or some concurrent medication).

Design outcomes

Primary

Measure	Time frame
Name: All-cause mortality, subdivided by severity of disease at the time of randomisation;Timepoints: At discharge or death;Measure: Discharge date or Cause of death	—

Secondary

Measure	Time frame
Name: Assess any effects of these anti-viral treatments on hospital duration and receipt of ventilation or intensive care ;Timepoints: During Hospitalization while on treatment;Measure: Clinical improvement ;Name: Identify any serious adverse reactions;Timepoints: During Hospitalization while on treatment;Measure: Any serious unexpected adverse reaction that is life-threatening (e.g. anaphylaxis, Stevens-Johnson syndrome, aplastic anaemia, or anything comparably strange) must be reported within 24 hours;Name: Virological cure;Timepoints: After Treatment is finalized ;Measure: PCR negative twice within 48hours	—

Measure

Time frame

Name: Assess any effects of these anti-viral treatments on hospital duration and receipt of ventilation or intensive care ;Timepoints: During Hospitalization while on treatment;Measure: Clinical improvement ;Name: Identify any serious adverse reactions;Timepoints: During Hospitalization while on treatment;Measure: Any serious unexpected adverse reaction that is life-threatening (e.g. anaphylaxis, Stevens-Johnson syndrome, aplastic anaemia, or anything comparably strange) must be reported within 24 hours;Name: Virological cure;Timepoints: After Treatment is finalized ;Measure: PCR negative twice within 48hours

—

Countries

Lebanon

Contacts

Public ContactRasha Hamra

MOPH

rashahamra@yahoo.com01-830300

Outcome results

None listed

Source: LBCTR (via WHO ICTRP) · Data processed: Feb 7, 2026